Eisai Gains Orion's Branded Generics Fareston And Eldepryl For China; Oncology Sales Force Can Be Seen In Action In Advance Of Halaven
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Eisai Inc. is tapping into China's opportunities for branded generics. The company announced July 13 it acquired marketing and distribution rights for Orion Corp.'s breast cancer drug Fareston (toremifene) and Parkinson's disease drug Eldepryl (selegiline), both of which are available as generics in China
You may also be interested in...
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
Pfizer Inc. and Shanghai-based Zhejiang Hisun Pharmaceuticals announced June 2 a memorandum of understanding to potentially establish a joint venture to develop, manufacture and sell branded generics in China and other markets
Eisai Revises Global Sales Strategy; Slashes U.S. Staff, Finds Ways To Retain Chinese Workers
TOKYO - Eisai Co., Ltd. is unable to meet all of the sales goals it set for its Dramatic Leap Plan, which probably comes as little surprise to most as the Japanese pharma struggles with patent losses of its blockbuster products, approval delays and R&D failures of key compounds. The company is responding by making its U.S. and European operations leaner, at the expense of hundreds of jobs, and stabilizing operations in emerging markets like China, where the company hopes to stem massive employee turnover by bringing staff to Japan for training
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).